Yes (first approved september 28, 2018) brand name Patel, md, discusses the fda approval of cemiplimab in cutaneous squamous cell carcinoma Regeneron pharmaceuticals) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (cscc) who are at a high risk of recurrence following surgery and radiation. The fda approves eylea hd the treatment of patients with macular edema following retinal vein occlusion. Last week, regeneron announced the u.s Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo
In a significant step forward for skin cancer management, the u.s
OPEN
